Amgen Buys Rights From Human Genome

Amgen Inc. of Thousand Oaks acquired rights from Human Genome Sciences Inc. to develop and sell potential treatments for cancer and immune deficiencies.

A statement by Human Genome didn’t disclose the price. The potential treatments and tests are based on a gene identified by the company.